Recent advances in multi-omics approaches encompassing genomics, transcriptomics, proteomics, and metabolomics offer hitherto unprecedented insights on common complex human diseases. A unique angle pertinent for both diagnostic and therapeutic sciences involves rethinking clinically distinct diseases with a view to their shared molecular targets, interactomes, and pathophysiologies. Reflecting at a scale of disease-to-disease associations might help clinicians, public health practitioners, drug and biotechnology developers, and associated knowledge industries in the current era. This review article examines the hypothesis that “Intersecting Molecular Pathways Permit Interventions on Multiple Clinical Endpoints”, thus uniquely bringing together Crohn's disease and periodontitis. Furthermore, we propose a novel connector molecular target between these two ostensibly distinct diseases at a clinical level, human beta defensin (hBD)-2, and suggest pathways by which hBD-2 can conceivably connect Crohn's disease and periodontitis by virtue of regulating the innate-immune response. We conclude by emphasizing different approaches where hBD-2 can be employed as a diagnostic and therapeutic tool to improve the quality of life of susceptible individuals and minimize the economic costs of these two major global public health problems. The strategy presented here also presents potentials for targeting of multiple diseases through a unique “nodal molecular target” that “speaks to” multiple clinical endpoints.
Get full access to this article
View all access options for this article.
References
1.
AldhousMC, NobleCL, and SatsangiJ. (2009). Dysregulation of human beta-defensin-2 protein in inflammatory bowel disease. PLoS One, 4, e6285.
2.
AnanthakrishnanAN. (2015). Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol, 12, 205–217.
3.
BentleyRW, PearsonJ, GearryRB, et al. (2010). Association of higher DEFB4 genomic copy number with Crohn's disease. Am J Gastroenterol, 105, 354–359.
4.
BoumaG, and StroberW. (2003). The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol, 3, 521–533.
5.
BritoF, de BarrosFC, ZaltmanC, et al. (2008). Prevalence of periodontitis and DMFT index in patients with Crohn's disease and ulcerative colitis. J Clin Periodontol, 35, 555–560.
6.
ChappleILC. (2014). Time to take periodontitis seriously. BMJ, 348, 2645.
7.
DimitrakopoulouK, DimitrakopoulosGN, SgarbasKN, and BezerianosA. (2014). Tamoxifen integromics and personalized medicine: Dynamic modular transformations underpinning response to tamoxifen in breast cancer treatment. OMICS, 18, 15–33.
8.
DudeneyTP. (1969). Crohn's disease of the mouth. Proc R Soc Med, 62, 1237.
9.
DyeBA. (2012). Global periodontal disease epidemiology. Periodontol 2000, 58, 10–25.
10.
EngelLD, PasquinelliKL, LeoneSA, MonclaBJ, NielsonKD, and RabinovitchPS. (1988). Abnormal lymphocyte profiles and leukotriene B4 status in a patient with Crohn's disease and severe periodontitis. J Periodontol, 59, 841–847.
11.
FellermannK, StangeDE, SchaeffelerE, SchmalzlH, WehkampJ, and BevinsCL. (2006). A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet, 79, 439–448.
12.
FlemmigTF, ShanahanF, and MiyasakiKT. (1991). Prevalence and severity of periodontal disease in patients with inflammatory bowel disease. J Clin Periodontol, 18, 690–697.
13.
FloydDN, LanghamS, SéveracHC, and LevesqueBG. (2015). The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: A systematic review. Dig Dis Sci, 60, 299–312.
14.
GaffenSL, and HajishengallisG. (2008). A new inflammatory cytokine on the block: Re-thinking periodontal disease and the Th1/Th2 paradigm in the context of Th17 cells and IL-17. J Dent Res, 87, 817–828.
15.
GarletGP. (2010). Destructive and protective roles of cytokines in periodontitis: A re-appraisal from host defense and tissue destruction viewpoints. J Dent Res, 89, 1349–1363.
16.
GhannamS, DejouC, PedrettiN, et al. (2011). CCL20 and β-defensin-2 induce arrest of human Th17 cells on inflamed endothelium in vitro under flow conditions. J Immunol, 186, 1411–1420.
17.
Grössner-SchreiberB, FetterT, HedderichJ, KocherT, SchreiberS, and JepsenS. (2006). Prevalence of dental caries and periodontal disease in patients with inflammatory bowel disease: S case-control study. J Clin Periodontol, 33, 478–484.
18.
GursoyUK, and KönönenE. (2012). Understanding the roles of gingival beta-defensins. J Oral Microbiol. 4.
19.
HabashnehRA, KhaderYS, AlhumouzMK, JadallahK, and AjlouniY. (2012). The association between inflammatory bowel disease and periodontitis among Jordanians: A case-control study. J Periodontal Res, 47, 293–298.
20.
HartyS, FlemingP, RowlandM, et al. (2005). A prospective study of the oral manifestations of Crohn's disease. Clin Gastroenterol Hepatol, 3, 886–891.
21.
IndrioloA, GrecoS, RavelliP, and FagiuoliS. (2011). What can we learn about biofilm/host interactions from the study of inflammatory bowel disease. J Clin Periodontol, 38, 36–43.
22.
JaradatSW, Hoder-PrzyrembelC, CubillosS, et al. (2013). Beta-defensin-2 genomic copy number variation and chronic periodontitis. J Dent Res, 92, 1035–1040.
23.
KandaN, KamataM, TadaY, IshikawaT, SatoS, and WatanabeS. (2011). Human β-defensin-2 enhances IFN-γ and IL-10 production and suppresses IL-17 production in T cells. J Leukoc Biol, 89, 935–944.
24.
KassebaumNJ, BernabéE, DahiyaM, BhandariB, MurrayCJ, and MarcenesW. (2014). Global burden of severe periodontitis in 1990–2010: A systematic review and meta-regression. J Dent Res, 93, 1045–1053.
KoldkjaerO, KlitgaardNA, and SchmidtKG. (1977). Indices of granulocyte activity in ulcerative colitis and Crohn's disease. Dan Med Bull, 24, 72.
27.
KornmanKS. (2008). Mapping the pathogenesis of periodontitis: A new look. J Periodontol, 79, 1560–1568.
28.
LamsterI, SonisS, HanniganA, and KolodkinA. (1978). An association between Crohn's disease, periodontal disease and enhanced neutrophil function. J Periodontol, 49, 475–479.
29.
LamsterIB, RodrickML, SonisST, and FalchukZM. (1982). An analysis of peripheral blood and salivary polymorphonuclear leukocyte function, circulating immune complex levels and oral status in patients with inflammatory bowel disease. J Periodontol, 53, 231–238.
30.
MathewsM, JiaHP, GuthmillerJM, et al. (1999). Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect Immun, 67, 2740–2745.
31.
MonteleoneI, VavassoriP, BianconeL, MonteleoneG, and PalloneF. (2002). Immunoregulation in the gut: Success and failures in human disease. Gut, 50, 11160–11164.
32.
NunesAP, OliveiraIO, SantosBR, et al. (2012). Quality of DNA extracted from saliva samples collected with the Oragene™ DNA self-collection kit. BMC Med Res Methodol, 12, 65.
33.
PietropaoliD, Del PintoR, CorridoniD, et al. (2014). Occurrence of spontaneous periodontal disease in the SAMP1/YitFc murine model of Crohn's disease. J Periodontol, 14, 1–8.
34.
PodderA, and LathaN. (2014). New insights into schizophrenia disease genes interactome in the human brain: Emerging targets and therapeutic implications in the postgenomics era. 18, 754–766.
35.
PolytarchouC, KoukosG, and IliopoulosD. (2014). Systems biology in inflammatory bowel diseases: Ready for prime time. Curr Opin Gastroenterol, 30, 339–346.
36.
RobertsHM, LingMR, InsallR, et al. (2015). Impaired neutrophil directional chemotactic accuracy in chronic periodontitis patients. J Clin Periodontol, 42, 1–11.
37.
SchaeferAS, BochenekG, JochensA, et al. (2015). Genetic evidence for PLASMINOGEN as a shared genetic risk factor of coronary artery disease and periodontitis. Circ Cardiovasc Genet, 8, 159–167.
38.
ScheperHJ, and BrandHS. (2002). Oral aspects of Crohn's disease. Int Dent J, 52, 163–172.
39.
SchulzS, ReichertS, StreetzK, et al. (2014). Tumor necrosis factor-α and oral inflammation in patients With Crohn disease. J Periodontol, 85, 1424–1431.
40.
SoutoGR, Queiroz-JuniorCM, de AbreuMH, CostaFO, and MesquitaRA. (2014). Pro-inflammatory, Th1, Th2, Th17 cytokines and dendritic cells: A cross-sectional study in chronic periodontitis. PLoS One, 9, e91636.
41.
SteinJM, LammertF, ZimmerV, et al. (2010). Clinical periodontal and microbiologic parameters in patients with Crohn's disease with consideration of the CARD15 genotype. J Periodontol, 81, 535–545.
42.
SunK, BuchanN, LarminieC, and PržuljN. (2014). The integrated disease network. Integr Biol (Camb), 6, 1069–1079.
43.
SunJ, ZhuK, ZhengW, and XuH. (2015). A comparative study of disease genes and drug targets in the human protein interactome. BMC Bioinformatics, 16, S1.
44.
SzczeklikK, OwczarekD, Pytko-PolonczykJ, KesekB, and MachTH. (2012). Proinflammatory cytokines in the saliva of patients with active and non-active Crohn's disease. Pol Arch Med Wewn, 122, 200–208.
45.
TetteyP, SimpsonSJr, TaylorBV, and van der MeiIA. (2015). The co-occurrence of multiple sclerosis and type 1 diabetes: Shared aetiologic features and clinical implication for MS aetiology. J Neurol Sci, 348, 126–131.
46.
ThomsonWM, and WilliamsSM. (2002). Partial- or full-mouth approaches to assessing the prevalence of and risk factors for periodontal disease in young adults. J Periodontol, 73, 1010–1014.
47.
Van DykeTE, DowellVRJr, OffenbacherS, SnyderW, and HershT. (1986). Potential role of microorganisms isolated from periodontal lesions in the pathogenesis of inflammatory bowel disease. Infect Immun, 53, 671–677.
48.
VavrickaSR, ManserCN, HedigerS, et al. (2013). Periodontitis and gingivitis in inflammatory bowel disease: A case-control study. Inflamm Bowel Dis, 19, 2768–2777.
49.
WehkampJ, FellermannK, HerrlingerKR, et al. (2002). Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol, 14, 745–752.
50.
WehkampJ, SchmidM, FellermannK, and StangeEF. (2005). Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol, 77, 460–465.
51.
ZhernakovaA, StahlEA, TrynkaG, et al. (2011). Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Gene, 7:e1002004.
